Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

p>1,252,4221,337,963   LONG-TERM DEBT

384,638363,696   DEFERRED TAX LIABILITIES, net

219,091159,328   OTHER LIABILITIES

279,049111,728Total liabilities

2,135,2001,972,715REDEEMABLE EQUITY

178,245207,307EQUITY:Cephalon Stockholders' Equity   Common stock, $0.01 par value

784780   Additional paid-in capital

2,407,5632,534,070   Treasury stock, at cost

(216,597)(208,427)   Accumulated earnings (deficit)

153,470(178,659)   Accumulated other comprehensive income

164,888114,194Total Cephalon stockholders' equity

2,510,1082,261,958Noncontrolling Interest

62,839216,115Total equity

2,572,9472,478,073$
4,886,392$
4,658,095CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months EndedSeptember 30,20102009CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$
324,278$
210,919Adjustments to reconcile net income to net cash provided by operating activities:Deferred income tax expense (benefit)

(27,976)(40,182)Depreciation and amortization

163,049136,403Stock-based compensation expense

31,74036,710Amortization of debt discount and debt issuance costs

51,31841,273Loss (gain) on foreign exchange contracts

9,499(26,754)Gain on acquisition of Arana

-(10,008)IPR&D from Acusphere deconsolidation

-8,366Other

1,749(5,079)Changes in operating assets and liabilities:Receivables

(1,006)94,204Inventory

31,967(7,060)Other assets

7,48032,206Accounts payable, accrued expenses and deferred revenues

53,39589,192Other liabilities

5,047(43,059)Net cash provided by operating activities

650,540517,131CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment

(34,989)(43,647)Proceeds from sale of property and equipment

4,748-Cash balance from consolidation of variable interest entity<
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... ... Ingredients for Follow-on Biologics in Chicago. , ... Chicago (Vocus) April 22, 2010 -- Therapeutic Proteins Inc. ... (or biosimilars) manufacturing facility constructed to meet U.S. Food and Drug Administration (FDA) requirements. ...
... iCardiac ... , ... (PRWEB) April 22, 2010 -- iCardiac Technologies, Inc., a provider of next generation cardiac ... a cardiac safety study leveraging iCardiac’s COMPAS technology platform including advanced ECG biomarker analyses., ...
... Promega Corporation now ... whole blood. , ... 21, 2010 -- Promega Corporation now offers the Maxwell® 16 LEV Blood DNA Kit ... work on the Maxwell® 16 instrument, eliminates the need for a buffy coat step while ...
Cached Biology Technology:Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... climate changes over the past several decades have led ... squirrels, birds and mosquitoes, according to University of Oregon ... the June 9 issue of SCIENCE, William E. Bradshaw, ... show that diverse animal populations have changed genetically in ...
... University of Florida scientists conducting experiments with mice have ... of cells in the eye essential for healthy vision. ... cell layer vital for eyesight called the retinal pigment ... writing in a recent issue of Investigative Ophthalmology & ...
... of human autoimmune disorders and other diseases works by dialing ... production, University of Michigan researchers have found. , "Many drugs ... Gary Glick, who is the Werner E. Bachmann Collegiate Professor ... volume control, so we're able to dial enzyme activity down ...
Cached Biology News:Recent, rapid climate change is driving evolution of animal species 2Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3Drug dials down the energy within cells, UM researchers find 2
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product contains a combination of 0.02% methylisothiazolone ... StabilCoat Plus Stabilizer provides optimum performance for ...
... Anti-PSD-95, clone K28/86.2, PDZ Domain ... Immunogen : GST fusion to residues ... 0.01M Tris pH 7.4, 0.075M NaCl ... routinely evaluated by immunoblot on rat ...
... Immunodepletion Kit specifically removes 20 of the ... serum in preparation for further proteomics analysis. ... plasma proteome whether you use one- or ... go straight to mass spectrometry. This is ...
Biology Products: